Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]LP-168 in healthy Chinese subjects
NCT06126861Phase 1Completed
- Sponsor
- Lupeng Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocbrutinib in B cell malignancies, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and 1 more, sponsored by Lupeng Pharmaceutical. Primary endpoints: Radioactivity concentration of blood and plasma sample, Radioactivity concentration of urine and feces sample and 1 more. Started Dec 2023; status: completed.
02
Drugs
rocbrutinib
03
Conditions
B cell malignancieschronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06126861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126861.